Agenus says BOT+BAL posts 33% three-year survival in Phase 1b MSS metastatic colorectal cancer cohort without active liver metastases

Agenus Inc.

Agenus Inc.

AGEN

0.00
  • Agenus reported 3-year Phase 1b data for botensilimab with balstilimab in refractory MSS metastatic colorectal cancer without active liver metastases.
  • Median overall survival was 21.2 months; 36-month overall survival rate was 33%, with a survival curve plateau beyond two years.
  • Confirmed objective response rate was 21%; median duration of response was not reached.
  • 21 patients, or 17%, were alive off systemic anticancer therapy at last follow-up.
  • Phase 3 BATTMAN trial continues in refractory MSS or pMMR metastatic colorectal cancer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260706344475) on July 06, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.